Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma announces Australian TGA approval of ILUMYA™

Posted On: 2018-09-21 11:59:07

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that Sun Pharma has received the Australian Therapeutic Goods Administration (TGA) approval for its speciality product, ILUMYA™ (tildrakizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

ILUMYA™ selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of proinflammatory cytokines and chemokines. ILUMYA™ is administered at a dose of 100 mg by subcutaneous injection every 12 weeks after the completion of initial doses at weeks 0 and 4. ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients in ILUMYA™, and in patients with clinically important active infections, e.g. active tuberculosis.

"We are pleased to have received this approval and look forward to bringing ILUMYA™ to dermatologists and patients in Australia," said Hellen De Kloet, Business Head, Western Europe & Australia, Sun Pharma. "We are launching a patient support program to assist patients prescribed with ILUMYA™. The program is designed to supplement the support offered by doctors in their practice or in hospital departments." she added.

The ILUMYA™ patient support program offers self-injection training by a registered nurse, dose reminders, injection consumables and a patient support help line.

ILUMYA™ is one of the key specialty products of Sun Pharma and it was approved by US FDA in March 2018 while the European Commission approved it in September 2018.

In Australia, the number of severe chronic plaque psoriasis patients receiving treatment through the Pharmaceutical Benefit Scheme (PBS) with biologics, increased by more than 60% between 2014 and 2016. However, the number treated was less than 30% of the severely affected population. The total PBS expenditure on biologicals for chronic plaque psoriasis (at published prices) was A$121 million in 20161.

The TGA approval of ILUMYA™ for the treatment of adults with moderate-to-severe plaque psoriasis was supported by data from the pivotal Phase-3 reSURFACE clinical development program. In the two multicentre, randomized, double-blind, placebo-controlled trials (reSURFACE 1 and reSURFACE 2), 1862 adult patients were enrolled and treated with ILUMYA™ (N=1238), etanercept (N=313) or placebo (N=310). Results from these studies were published in The Lancet in July 2017, with primary endpoints presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress. Both Phase-3 studies met the primary efficacy endpoints, demonstrating significant clinical improvement with ILUMYA™ 100 mg compared to placebo or etanercept when measured by at least 75 percent reduction in baseline psoriasis severity (Psoriasis Area Sensitivity Index or PASI 75) and Physician's Global Assessment (PGA) score of "clear" or "minimal" at week 12 after two doses.

The most common adverse reactions observed with ILUMYA™ in the pooled data from one Phase 2 and two Phase 3 studies in psoriasis patients for the placebo controlled period (16 weeks for the Phase 2 study and 12 weeks for the Phase 3 studies) were nasopharyngitis, headache, and site injection pain. Most adverse reactions were considered mild and no adverse reaction led to discontinuation of treatment in >1% of patients.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.647.3 as compared to the previous close of Rs. 642.3. The total number of shares traded during the day was 596394 in over 9646 trades.

The stock hit an intraday high of Rs. 657 and intraday low of 640.2. The net turnover during the day was Rs. 386413178.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

G N A Axles Ltd Q2 FY19 PAT jumps to Rs. 16.24 crores

TVS Motor Company Ltd Q2 FY19 net profit slips to Rs. 211.31 crores

Rane Brake Lining Ltd Q2 net profit falls to Rs. 5.30 crores

Super Sales India Ltd Q2 FY19 PAT slips to Rs. 6.95 crores

Performance highlights RBL Bank for Half year ended September 30, 2018 - H1 FY19

Performance highlights of RBL Bank for Quarter ended September 30, 2018 - Q2 FY19

Laurus Labs Ltd board to approve quarterly results on Nov 1, 2018

RBL Bank reports advances growth of 37% in Q2 FY19

TCS' Quartz Blockchain Solution powers Landmark Cross-Border Data Exchange in Africa

Ahluwalia Contracts secures new order of Rs. 538.76 crores

RBL Bank Ltd Q2 FY19 PAT climbs to Rs. 204.54 crores

EXPO Gas Containers Ltd calls for board meeting on Nov 5, 2018

Brunei's Largest Bank Bank Islam Brunei Darussalam Berhad Goes Live on Ramco ERP

iGTB and R3 partner for next-gen blockchain-enabled financial technology platform solutions

Suven to present at 11TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE during October 24-27, 2018 - BARCELONA, SPAIN

Ramco Systems Ltd board to approve Q2 FY19 results on Oct 31, 2018

Precision Camshafts Ltd board to announce second quarter results on Nov 14, 2018

Bajaj Hindusthan Sugar Limited board to consider Q2 results on Nov 2, 2018

Gandhi Special Tubes Ltd board to approve 2nd quarter results on Oct 31, 2018

GlaxoSmithkline Consumer Healthcare Ltd calls for board meeting on Nov 1, 2018

Bharat Forge Ltd Board to consider Interim Dividend on Nov 2, 2018

Bajaj Housing Finance Ltd H1 FY19 PAT rises to Rs. 11.38 crores

Oberoi Realty Limited announces Q2FY19 and H1FY19 results

GlaxoSmithKline Pharmaceuticals delivers strong H1 performance

Himachal Futuristic Communications Ltd receives order worth Rs. 366.36 crore

SNL Bearings Ltd calls for board meeting on Oct 30, 2018

The Mandhana Retail Ventures Ltd board to consider quarterly, half-yearly results

Bhushan Steel Limited board to approve second quarter results on Oct 30, 2018

Shemaroo Entertainment Ltd board to consider Q2, H1 results on Oct 30, 2018

Inditrade Capital Limited board to announce quarterly results on Nov 2, 2018

HGS's AxisPoint Health Earns Health Call Center URAC Reaccreditation

Speciality Restaurants Ltd board to consider Q2, H1 FY19 results on Nov 3, 2018

ITD Cementation Wins Orders Valued over INR 1066 Crores

Navneet Education Limited board to announce Q2 FY19 results on Oct 31, 2018

Asian Paints Ltd approves interim dividend of Rs. 2.85

IFB Industries Ltd updates on acquisition status

TeamLease Services Ltd board to approve Q2, H1 results on Oct 30, 2018

Filatex India Ltd board to announce second quarter results on Oct 31, 2018

Man Industries India Ltd board to consider 2nd quarter result son Oct 29, 2018

Sharda Cropchem Ltd board to approve Q2 results on Oct 31, 2018

GTN Textiles Ltd calls for board meeting on Nov 5, 2018

Patspin India Ltd calls for board meeting on Nov 5, 2018

CCL Products India Ltd Q2 FY19 net profit higher at Rs. 47.18 crores

Omax Autos Ltd Q2 loss at Rs. 1.49 crore

Welspun India Ltd Q2 PAT up at Rs. 121.69 crores

Lakshmi Machine Works Ltd Q2 net profit falls to Rs. 40.42 crores

Oberoi Realty Ltd Q2 net profit soars to Rs. 213.83 crores

Asian Paints Ltd Q2 FY19 PAT slides to Rs. 506 crores

Genus Power Infrastructures Ltd Q2 net profit climbs to Rs. 12.37 crores

Everest Organics Ltd receives closure order for factory at Sadasivapet, Telangana







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2018